{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:20Z","timestamp":1788316820179,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xiangyang Central Hospital hospital-level project","award":["2022YB14"],"award-info":[{"award-number":["2022YB14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the predictive value of serum levels of Interleukin-6 (IL-6), interleukin-17 (IL-17), soluble suppression of tumorigenicity 2 protein (sST2) for diuretic resistance in patients with chronic heart failure (CHF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      His retrospective cohort study enrolled patients with CHF patients treated at Xiangyang Central Hospital between July 2019 and July 2022. Participants were categorized into two groups: the diuretic resistance (DR) group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200970) and non-DR group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200980). Diuretic resistance was established by a urine output\u2009&lt;\u20090.5\u20131.0 mL\/kg\/h following the administration of \u2265\u200980\u00a0mg of furosemide. General clinical data and serum indexes were compared between groups. Multivariate logistic regression identified independent DR risk factors. Bootstrap resampling (1000 replicates) was used to estimate 95% confidence intervals for the area under the curve, sensitivity, and specificity in receiver operating characteristic analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics, including age, sex, and comorbidities, were comparable between the diuretic resistance (DR) and non-DR groups (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). Compared with the non-DR group, patients with DR exhibited significantly lower urine output and urinary sodium concentration, alongside impaired renal function (higher Cr and lower eGFR), hypoalbuminemia, and elevated liver enzymes (ALT) (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Furthermore, inflammatory markers (WBC, IL-6, IL-17, sST2) and cardiac dysfunction indicators (NT-proBNP, LVEDd, LAVI, and TRPG) were significantly elevated in the DR group (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). After adjusting for age, LVEF, and eGFR in the multivariate logistic regression, IL-6 (OR: 1.860 per 10 pg\/mL), IL-17 (OR: 1.952 per 10 pg\/mL), and sST2 (OR: 1.450 per 10\u00a0\u00b5g\/L) remained independently associated with the risk of diuretic resistance (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). ROC curves analysis revealed that combined assessment of IL-6, IL-17 and sST2 provided the highest predictive accuracy for diuretic resistance, with an AUC of 0.861 (95% bootstrapped CI: 0.795\u20130.912), a sensitivity of 81.43%, and a specificity of 86.25%, outperforming individual biomarkers (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum IL-6, IL-17, and sST2 levels are associated with diuretic resistance in hospitalized patients with chronic heart failure. The integration of these biomarkers may provide enhanced predictive value for identifying diuretic resistance compared to individual assessments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05756-2","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:46:40Z","timestamp":1776077200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive accuracy of serum IL-6, IL-17 and sST2 levels for diuretic resistance in patients with chronic heart failure"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0559-0623","authenticated-orcid":false,"given":"Dingjun","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3308-0711","authenticated-orcid":false,"given":"Cong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1446-0031","authenticated-orcid":false,"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6557-0758","authenticated-orcid":false,"given":"Dongdong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1987-7945","authenticated-orcid":false,"given":"Wanyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3910-8932","authenticated-orcid":false,"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"5756_CR1","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel OJE. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. 2021, 42(36):3599\u2013726.","DOI":"10.1093\/eurheartj\/ehab670"},{"key":"5756_CR2","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LRJJACC. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. 2022, 79(17):e263\u2013421.","DOI":"10.1161\/CIR.0000000000001063"},{"issue":"4","key":"5756_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11897-024-00659-9","volume":"21","author":"JC Trull\u00e0s","year":"2024","unstructured":"Trull\u00e0s JC, Casado J, Cobo-Marcos M, Formiga F, Morales-Rull JL, N\u00fa\u00f1ez J, Manzano L. Combinational Diuretics in Heart Failure. Curr Heart Fail Rep. 2024;21(4):1\u201311.","journal-title":"Curr Heart Fail Rep"},{"key":"5756_CR4","doi-asserted-by":"publisher","first-page":"114334","DOI":"10.1016\/j.biopha.2023.114334","volume":"161","author":"R Gelman","year":"2023","unstructured":"Gelman R, Hurvitz N, Nesserat R, Kolben Y, Nachman D, Jamil K, Agus S, Asleh R, Amir O, Berg M, et al. A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial. Biomed Pharmacother. 2023;161:114334.","journal-title":"Biomed Pharmacother"},{"key":"5756_CR5","doi-asserted-by":"crossref","unstructured":"Wilcox CS, Testani JM, Pitt BJH. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. 2020, 76(4):1045\u201354.","DOI":"10.1161\/HYPERTENSIONAHA.120.15205"},{"issue":"1","key":"5756_CR6","first-page":"e002370","volume":"9","author":"JM Testani","year":"2016","unstructured":"Testani JM, Hanberg JS, Cheng S, Rao V, Onyebeke C, Laur O, Kula A, Chen M, Wilson FP, Darlington A, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation: Heart Fail. 2016;9(1):e002370.","journal-title":"Circulation: Heart Fail"},{"key":"5756_CR7","doi-asserted-by":"crossref","unstructured":"Hubbell KT, Rao VS, Scherzer R, Shlipak MG, Ivery-Miranda JB, Bansal N, Cox ZL, Testani JM, Estrella MMJEHF. Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure. 2025.","DOI":"10.1002\/ehf2.15342"},{"key":"5756_CR8","doi-asserted-by":"publisher","first-page":"114058","DOI":"10.1016\/j.biopha.2022.114058","volume":"157","author":"L Guo","year":"2023","unstructured":"Guo L, Fu B, Liu Y, Hao N, Ji Y, Yang H. Diuretic resistance in patients with kidney disease: Challenges and opportunities. Biomed Pharmacother. 2023;157:114058.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5756_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cyto.2014.12.024","volume":"74","author":"JA Fontes","year":"2015","unstructured":"Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine. 2015;74(1):62\u20138.","journal-title":"Cytokine"},{"key":"5756_CR10","doi-asserted-by":"publisher","first-page":"1465625","DOI":"10.3389\/fimmu.2024.1465625","volume":"15","author":"L Zhang","year":"2024","unstructured":"Zhang L, Xu F, Hou L. IL-6 and diabetic kidney disease. Front Immunol. 2024;15:1465625.","journal-title":"Front Immunol"},{"issue":"3","key":"5756_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.yexmp.2009.06.001","volume":"87","author":"W Feng","year":"2009","unstructured":"Feng W, Li W, Liu W, Wang F, Li Y, Yan W. IL-17 induces myocardial fibrosis and enhances RANKL\/OPG and MMP\/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol. 2009;87(3):212\u20138.","journal-title":"Exp Mol Pathol"},{"issue":"4","key":"5756_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3325\/cmj.2018.59.139","volume":"59","author":"Z Rahmati","year":"2018","unstructured":"Rahmati Z, Amirzargar AA, Saadati S, Rahmani F, Mahmoudi MJ, Rahnemoon Z, Eskandari V, Gorzin F, Hedayat M, Rezaei N. Association of levels of interleukin 17 and T-helper 17 count with symptom severity and etiology of chronic heart failure: a case-control study. Croat Med J. 2018;59(4):139\u201348.","journal-title":"Croat Med J"},{"key":"5756_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000349968","volume":"182","author":"DN Cruz","year":"2013","unstructured":"Cruz DN, Schmidt-Ott KM, Vescovo G, House AA, Kellum JA, Ronco C, McCullough PA. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:117\u201336.","journal-title":"Contrib Nephrol"},{"issue":"2","key":"5756_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223","volume":"4","author":"B Ky","year":"2011","unstructured":"Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4(2):180\u20137.","journal-title":"Circ Heart Fail"},{"issue":"3","key":"5756_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10875-011-9622-7","volume":"32","author":"YS Bao","year":"2012","unstructured":"Bao YS, Na SP, Zhang P, Jia XB, Liu RC, Yu CY, Mu SH, Xie RJ. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J Clin Immunol. 2012;32(3):587\u201394.","journal-title":"J Clin Immunol"},{"issue":"04","key":"5756_CR16","first-page":"257","volume":"40","author":"DONG Wei","year":"2024","unstructured":"Wei DONG, Dongjie RJXU. Chinese expert consensus on the diagnosis and management of diuretic resistance in patients with heart failure. J Clin Cardiol. 2024;40(04):257\u201367.","journal-title":"J Clin Cardiol"},{"key":"5756_CR17","first-page":"760","volume":"46","author":"H Association","year":"2018","unstructured":"Association H, Association C, Cardiology E. Chinese guidelines for the diagnosis and treatment of heart failure 2018. Chin J Cardiol. 2018;46:760\u201389.","journal-title":"Chin J Cardiol"},{"key":"5756_CR18","doi-asserted-by":"crossref","unstructured":"Bank AJ, Rischall A, Fau - Gage RM, Gage Rm Fau - Burns KV, Burns Kv Fau -, Kubo SH, Kubo SH. Comparison of cardiac resynchronization therapy outcomes in patients with New York Heart Association functional class I\/II versus III\/IV heart failure. Journal of cardiac failure 2012, 18(5):373\u2013378.","DOI":"10.1016\/j.cardfail.2012.01.015"},{"issue":"3","key":"5756_CR19","first-page":"178","volume":"16","author":"WZ Zhang","year":"2019","unstructured":"Zhang WZ. Intensified, optimized and standardized management of Chinese patients with hypertension: Comments on 2018 Chinese Guidelines for Prevention and Treatment of Hypertension. J geriatric cardiology:JGC. 2019;16(3):178.","journal-title":"J geriatric cardiology:JGC"},{"issue":"2","key":"5756_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.cardfail.2024.09.002","volume":"31","author":"JAN Biegus","year":"2025","unstructured":"Biegus JAN, Cotter GAD, Davison BA, Freund Y, Voors AA, Edwards C, Novosadova M, Takagi K, Hayrapetyan H, Mshetsyan A, et al. The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial. J Card Fail. 2025;31(2):354\u201366.","journal-title":"J Card Fail"},{"key":"5756_CR21","doi-asserted-by":"crossref","unstructured":"Zhu X, Cheang I, Xu F, Gao R, Liao S, Yao W, Zhou Y, Zhang H, Li XJF. Long-term prognostic value of inflammatory biomarkers for patients with acute heart failure: Construction of an inflammatory prognostic scoring system. 2022, 13:1005697.","DOI":"10.3389\/fimmu.2022.1005697"},{"issue":"4","key":"5756_CR22","first-page":"741","volume":"8","author":"A Lala","year":"2015","unstructured":"Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, et al. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circulation: Heart Fail. 2015;8(4):741\u20138.","journal-title":"Circulation: Heart Fail"},{"issue":"32","key":"5756_CR23","doi-asserted-by":"publisher","first-page":"11766","DOI":"10.12998\/wjcc.v10.i32.11766","volume":"10","author":"L Xu","year":"2022","unstructured":"Xu L, Lu LL, Wang YT, Zhou JB, Wang CX, Xin JD, Gao JD. Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1\u20132 and 3\u20134. World J Clin Cases. 2022;10(32):11766.","journal-title":"World J Clin Cases"},{"key":"5756_CR24","doi-asserted-by":"crossref","unstructured":"Barutaut M, Fournier P, Peacock WF, Evaristi M-F, Dambrin C, Caub\u00e8re C, Koukoui F, Galinier M, Smih F. Rouet PJAc: sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. 2020, 75(8):739\u201347.","DOI":"10.1080\/00015385.2019.1669847"},{"issue":"6","key":"5756_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/clc.23187","volume":"42","author":"PA-O Mills","year":"2019","unstructured":"Mills PA-O, Taub PR, Lunde O, Pung MA, Wilson K, Pruitt C, Rutledge T, Maisel A, Greenberg BH. Depressive symptoms in asymptomatic stage B heart failure with Type II diabetic mellitus. Clin Cardiol. 2019;42(6):637\u201343.","journal-title":"Clin Cardiol"},{"key":"5756_CR26","doi-asserted-by":"crossref","unstructured":"Bombicino SS, Iglesias DE, Mikusic IAR, D\u2019Annunzio V, Gelpi RJ, Boveris A. Valdez LBJTijob, biology c: Diabetes impairs heart mitochondrial function without changes in resting cardiac performance. 2016, 81:335\u201345.","DOI":"10.1016\/j.biocel.2016.09.018"},{"key":"5756_CR27","doi-asserted-by":"crossref","unstructured":"Biegus J, Nawrocka-Millward S, Zymli\u0144ski R, Fudim M, Testani J, Marciniak D, Rosiek-Biegus M, Ponikowska B, Guzik M. Garus MJIJoC: Distinct renin\/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. 2021, 345:54\u201360.","DOI":"10.1016\/j.ijcard.2021.10.149"},{"key":"5756_CR28","doi-asserted-by":"crossref","unstructured":"Biegus J, Zymli\u0144ski R, Testani J, Marciniak D, Zdanowicz A, Jankowska EA, Banasiak W. Ponikowski PJEjohf: Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. 2021, 23(5):729\u201339.","DOI":"10.1002\/ejhf.2053"},{"key":"5756_CR29","doi-asserted-by":"crossref","unstructured":"Segev A, Itelman E, Avaky C, Negru L, Shenhav-Saltzman G, Grupper A, Wasserstrum Y. Segal GJJoCM: Low ALT levels associated with poor outcomes in 8700 hospitalized heart failure patients. 2020, 9(10):3185.","DOI":"10.3390\/jcm9103185"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05756-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05756-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05756-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:56:20Z","timestamp":1781646980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05756-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5756"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05756-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Xiangyang Central Hospital in accordance with regulatory and ethical guidelines pertaining to retrospective research studies (Ethical approval No. 2023-043) on 11th April 2023. Informed consent was waived for this retrospective study due to the exclusive use of de-identified patient data, which posed no potential harm or impact on patient care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"448"}}